Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Graves' Ophthalmopathy
NCT03922321Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- Apr 2019
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of batoclimab in Graves' ophthalmopathy (TED), sponsored by Immunovant, Inc. Primary endpoints: Treatment-emergent Adverse Events at 6 weeks, Vital Signs at 18 weeks and 4 more. Started Apr 2019; status: completed.
02
Drugs
batoclimab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT03922321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922321.